Brightsurf Science News & Current Events

September 29, 2012
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer
Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer, according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

Combination of targeted treatment drugs delays resistance in melanoma patients
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

Studies show advances in gastrointestinal cancer treatments
New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

Lack of sleep leads to insulin resistance in teens
A new study suggests that increasing the amount of sleep that teenagers get could improve their insulin resistance and prevent the future onset of diabetes.

Governments failing to address 'global pandemic of untreated cancer pain'
Governments around the world are leaving hundreds of millions of cancer patients to suffer needlessly because of their failure to ensure adequate access to pain-relieving drugs, an unprecedented new international survey reveals.

Studies show drug combinations effective for melanoma
Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

Moffitt Cancer Center researcher helps develop prostate cancer testing, treatment guidelines
Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN -- The Journal of the National Comprehensive Cancer Network.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.